NIRMATRELVIR

It is a SARS-CoV-2 main protease (Mpro) inhibitor. The U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for the emergency use of the unapproved product for the treatment of mild-to-moderate coronavirus disease 2019 (COVID-19) in adults and pediatric patients (12 years of age and older weighing at least 40 kg) with positive results of direct severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral testing, and who are at high risk1 for progression to severe COVID-19, including hospitalization or death. It is not approved for any use, including for use for the treatment of COVID-19.

Indications

Oral; 300 mg nirmatrelvir (two 150 mg tablets) with ritonavir taken together orally twice daily for 5 days. Completion of the full 5-day treatment course and continued isolation in accordance with public health recommendations are important to maximize viral clearance and minimize transmission of SARS-CoV-2.

Dosage

Oral; 300 mg nirmatrelvir (two 150 mg tablets) with ritonavir taken together orally twice daily for 5 days. Completion of the full 5-day treatment course and continued isolation in accordance with public health recommendations are important to maximize viral clearance and minimize transmission of SARS-CoV-2.

Contra-Indications

Hypersensitivity

Special Precautions

Paediatric: Safety and efficacy in pediatric patients have not been established Pregnancy: : Data not sufficient Lactation: Data not sufficient Elderly: Data not sufficient.

Side Effects

Diarrhea, myalgia, altered sense of taste, and high blood pressure, hives, difficulty breathing, swelling of your face, lips, tongue, or throat, severe dizziness, and abnormal lab test results

Drug Interactions

Alfuzosin, pethidine, piroxicam, propoxyphene, lidocaine.